Navigation Links
Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin,Emerging Growth Opportunities Conference

DURHAM, N.C.--(BUSINESS WIRE)--Jul 3, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Christy L. Shaffer, Ph.D., President and CEO, will present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference on Wednesday, July 11, 2007 at 11:00 am ET in New York City.

The webcast of the presentation will be available on Inspire's web site at www.inspirepharm.com. An archived version of the webcast presentation will also be available through this link for a limited time following the conference.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Contact

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin
VP, Investor Relations and Corporate Communications
919-941-9777, ext. 219
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007 ext. 14


'"/>




Page: 1

Related medicine technology :

1. Inspire Announces Presentations at Two European Scientific Conferences
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2019)... FLORENCE, Ky. (PRWEB) , ... February 15, 2019 ... ... Ryan Estes and Dr. Allison Marlow of Perio-Implant Care are urging patients to ... heart disease, stroke, certain cancers, diabetes, Alzheimer's and dementia, and risk of pre-term ...
(Date:2/16/2019)... ... February 15, 2019 , ... Dr. Lucas Bryant, board-certified ... , The Haute Beauty Network, well known for their exclusivity, and luxurious lifestyle, ... and our newest addition to the Haute Living partnership. , Haute Beauty offers ...
(Date:2/14/2019)... ... February 14, 2019 , ... In this month’s ... Professor of Education Gregory A. Smith speaks with Christopher Saldaña, Doctoral Student Researcher ... programs, a new phenomenon in the marketing of educational resources to schools. , ...
Breaking Medicine Technology:
(Date:2/14/2019)... ... February 14, 2019 , ... KICVentures , an investment ... specific purpose of preparing its two disruptive spine portfolio companies, AxioMed LLC ... 3-5 years. , The spine industry is consolidating evidenced by multiple acquisitions ...
(Date:2/13/2019)... ... February 14, 2019 , ... At this year’s Market America ... their feet and cheered as it was announced that the company was now ranked ... last few years, the company has optimized its revolutionary “Shopping Annuity” program, making it ...
(Date:2/13/2019)... INDIANAPOLIS (PRWEB) , ... February 13, 2019 , ... ... playgrounds and in high school locker rooms. Unfortunately, bullies also frequent hospital units, ... colleagues and peers. , In this fully updated, second edition of What ...
(Date:2/13/2019)... (PRWEB) , ... February 13, ... ... healthcare innovation community announced ‘ Energizing Health @ SXSW ,’ four days ... on creating opportunities for community advocates, entrepreneurs, health organizations, industry and philanthropy ...
(Date:2/13/2019)... ... February 13, 2019 , ... Intalere will hold its ... conference, Elevate 2019 at the Gaylord Rockies Resort & Convention Center, Denver, Colo. ... partnerships driving improved quality of patient care, reduced costs and enhanced revenue opportunities ...
Breaking Medicine News(10 mins):